Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 4 Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Solid Tumors 1 Rectal Neoplasms 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1

Interventions

Injections 25 Carboplatin 17 Docetaxel 14 pembrolizumab 12 Paclitaxel 11 Bevacizumab 9 durvalumab 8 Cisplatin 8 Nivolumab 6 Fluorouracil 6 trifluridine tipiracil drug combination 5 tislelizumab 5 linifanib 5 Pemetrexed 5 Oxaliplatin 5 Leucovorin 5 zimberelimab 4 toripalimab 4 talazoparib 4 olaparib 4 Itraconazole 4 Irinotecan 4 Gemcitabine 4 Capecitabine 4 tremelimumab 3 sotorasib 3 sintilimab 3 fludarabine 3 depatuxizumab 3 atezolizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Solid Tumors × dalotuzumab × Clear all

NCT00635778 2018-10-09

MK-0646-002

Merck Sharp & Dohme LLC

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡